ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
"áCIDOS HETEROARILALCANóICOS COMO DERIVADOS DE ANTAGONISTAS DE RECEPTOR DE INTEGRINA". A presente invenção refere-se a composições farmacêuticas compreendendo compostos da Fórmula I, ou um seu sal farmaceuticamente aceitável, e métodos de inibição ou antagonização seletiva da ~ v~ ~ 6~ e/o...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | por |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | HEATHER STENMARK DALE P. SPANGLER VICTORIA DOWNS GLEN J. GESICKI LISA WU JOHN A. WENDT MICHAEL B. TOLLEFSON MARK RUSSELL SRINIVASAN R. NAGARAJAN ALBERT KHILEVICH YI YU MARK L. BOYS RENEE M. HUFF BIPINCHANDRA N. DESAI LORI A. SCHRETZMAN NIZAL S. CHANDRAKUMAR SCOTT B. MOHLER YAPING WANG MIHIR D. PARIKH THOMAS D. PENNING BARBARA B. CHEN ISH K. KHANNA MARIA NGUYEN BALEKUDRU DEVADAS HWANG-FUN LU |
| description | "áCIDOS HETEROARILALCANóICOS COMO DERIVADOS DE ANTAGONISTAS DE RECEPTOR DE INTEGRINA". A presente invenção refere-se a composições farmacêuticas compreendendo compostos da Fórmula I, ou um seu sal farmaceuticamente aceitável, e métodos de inibição ou antagonização seletiva da ~ v~ ~ 6~ e/ou da ~ v~ ~ 5~ integrina sem significantemente inibir ~ v~ ~6~ integrina.
The present invention relates to pharmaceutical compositions comprising compounds of the Formula I, or a pharmaceutically acceptable salt thereof, and methods of selectively inhibiting or antagonizing the alphaVbeta3 and/or the alphaVbeta5 integrin without significantly inhibiting the alphaVbeta6 integrin. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_BR0317600A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>BR0317600A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_BR0317600A3</originalsourceid><addsrcrecordid>eNrjZAg9vDA5MyW_WCEjtSS1KD-xKDMnMSc5Me_w5sxkoGhyfm6-QkpqUWZZIkhRSqpCYl5JYnp-XmZxSSKYX5SanFpQkl8EYmfmlaSmF2XmJfIwsKYl5hSn8kJpbgZ5N9cQZw_d1IL8-NTigsTk1LzUkninIANjQ3MzAwNHY8IqACWsOkM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina</title><source>esp@cenet</source><creator>HEATHER STENMARK ; DALE P. SPANGLER ; VICTORIA DOWNS ; GLEN J. GESICKI ; LISA WU ; JOHN A. WENDT ; MICHAEL B. TOLLEFSON ; MARK RUSSELL ; SRINIVASAN R. NAGARAJAN ; ALBERT KHILEVICH ; YI YU ; MARK L. BOYS ; RENEE M. HUFF ; BIPINCHANDRA N. DESAI ; LORI A. SCHRETZMAN ; NIZAL S. CHANDRAKUMAR ; SCOTT B. MOHLER ; YAPING WANG ; MIHIR D. PARIKH ; THOMAS D. PENNING ; BARBARA B. CHEN ; ISH K. KHANNA ; MARIA NGUYEN ; BALEKUDRU DEVADAS ; HWANG-FUN LU</creator><creatorcontrib>HEATHER STENMARK ; DALE P. SPANGLER ; VICTORIA DOWNS ; GLEN J. GESICKI ; LISA WU ; JOHN A. WENDT ; MICHAEL B. TOLLEFSON ; MARK RUSSELL ; SRINIVASAN R. NAGARAJAN ; ALBERT KHILEVICH ; YI YU ; MARK L. BOYS ; RENEE M. HUFF ; BIPINCHANDRA N. DESAI ; LORI A. SCHRETZMAN ; NIZAL S. CHANDRAKUMAR ; SCOTT B. MOHLER ; YAPING WANG ; MIHIR D. PARIKH ; THOMAS D. PENNING ; BARBARA B. CHEN ; ISH K. KHANNA ; MARIA NGUYEN ; BALEKUDRU DEVADAS ; HWANG-FUN LU</creatorcontrib><description>"áCIDOS HETEROARILALCANóICOS COMO DERIVADOS DE ANTAGONISTAS DE RECEPTOR DE INTEGRINA". A presente invenção refere-se a composições farmacêuticas compreendendo compostos da Fórmula I, ou um seu sal farmaceuticamente aceitável, e métodos de inibição ou antagonização seletiva da ~ v~ ~ 6~ e/ou da ~ v~ ~ 5~ integrina sem significantemente inibir ~ v~ ~6~ integrina.
The present invention relates to pharmaceutical compositions comprising compounds of the Formula I, or a pharmaceutically acceptable salt thereof, and methods of selectively inhibiting or antagonizing the alphaVbeta3 and/or the alphaVbeta5 integrin without significantly inhibiting the alphaVbeta6 integrin.</description><edition>7</edition><language>por</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2005</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20051129&DB=EPODOC&CC=BR&NR=0317600A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20051129&DB=EPODOC&CC=BR&NR=0317600A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HEATHER STENMARK</creatorcontrib><creatorcontrib>DALE P. SPANGLER</creatorcontrib><creatorcontrib>VICTORIA DOWNS</creatorcontrib><creatorcontrib>GLEN J. GESICKI</creatorcontrib><creatorcontrib>LISA WU</creatorcontrib><creatorcontrib>JOHN A. WENDT</creatorcontrib><creatorcontrib>MICHAEL B. TOLLEFSON</creatorcontrib><creatorcontrib>MARK RUSSELL</creatorcontrib><creatorcontrib>SRINIVASAN R. NAGARAJAN</creatorcontrib><creatorcontrib>ALBERT KHILEVICH</creatorcontrib><creatorcontrib>YI YU</creatorcontrib><creatorcontrib>MARK L. BOYS</creatorcontrib><creatorcontrib>RENEE M. HUFF</creatorcontrib><creatorcontrib>BIPINCHANDRA N. DESAI</creatorcontrib><creatorcontrib>LORI A. SCHRETZMAN</creatorcontrib><creatorcontrib>NIZAL S. CHANDRAKUMAR</creatorcontrib><creatorcontrib>SCOTT B. MOHLER</creatorcontrib><creatorcontrib>YAPING WANG</creatorcontrib><creatorcontrib>MIHIR D. PARIKH</creatorcontrib><creatorcontrib>THOMAS D. PENNING</creatorcontrib><creatorcontrib>BARBARA B. CHEN</creatorcontrib><creatorcontrib>ISH K. KHANNA</creatorcontrib><creatorcontrib>MARIA NGUYEN</creatorcontrib><creatorcontrib>BALEKUDRU DEVADAS</creatorcontrib><creatorcontrib>HWANG-FUN LU</creatorcontrib><title>ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina</title><description>"áCIDOS HETEROARILALCANóICOS COMO DERIVADOS DE ANTAGONISTAS DE RECEPTOR DE INTEGRINA". A presente invenção refere-se a composições farmacêuticas compreendendo compostos da Fórmula I, ou um seu sal farmaceuticamente aceitável, e métodos de inibição ou antagonização seletiva da ~ v~ ~ 6~ e/ou da ~ v~ ~ 5~ integrina sem significantemente inibir ~ v~ ~6~ integrina.
The present invention relates to pharmaceutical compositions comprising compounds of the Formula I, or a pharmaceutically acceptable salt thereof, and methods of selectively inhibiting or antagonizing the alphaVbeta3 and/or the alphaVbeta5 integrin without significantly inhibiting the alphaVbeta6 integrin.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2005</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZAg9vDA5MyW_WCEjtSS1KD-xKDMnMSc5Me_w5sxkoGhyfm6-QkpqUWZZIkhRSqpCYl5JYnp-XmZxSSKYX5SanFpQkl8EYmfmlaSmF2XmJfIwsKYl5hSn8kJpbgZ5N9cQZw_d1IL8-NTigsTk1LzUkninIANjQ3MzAwNHY8IqACWsOkM</recordid><startdate>20051129</startdate><enddate>20051129</enddate><creator>HEATHER STENMARK</creator><creator>DALE P. SPANGLER</creator><creator>VICTORIA DOWNS</creator><creator>GLEN J. GESICKI</creator><creator>LISA WU</creator><creator>JOHN A. WENDT</creator><creator>MICHAEL B. TOLLEFSON</creator><creator>MARK RUSSELL</creator><creator>SRINIVASAN R. NAGARAJAN</creator><creator>ALBERT KHILEVICH</creator><creator>YI YU</creator><creator>MARK L. BOYS</creator><creator>RENEE M. HUFF</creator><creator>BIPINCHANDRA N. DESAI</creator><creator>LORI A. SCHRETZMAN</creator><creator>NIZAL S. CHANDRAKUMAR</creator><creator>SCOTT B. MOHLER</creator><creator>YAPING WANG</creator><creator>MIHIR D. PARIKH</creator><creator>THOMAS D. PENNING</creator><creator>BARBARA B. CHEN</creator><creator>ISH K. KHANNA</creator><creator>MARIA NGUYEN</creator><creator>BALEKUDRU DEVADAS</creator><creator>HWANG-FUN LU</creator><scope>EVB</scope></search><sort><creationdate>20051129</creationdate><title>ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina</title><author>HEATHER STENMARK ; DALE P. SPANGLER ; VICTORIA DOWNS ; GLEN J. GESICKI ; LISA WU ; JOHN A. WENDT ; MICHAEL B. TOLLEFSON ; MARK RUSSELL ; SRINIVASAN R. NAGARAJAN ; ALBERT KHILEVICH ; YI YU ; MARK L. BOYS ; RENEE M. HUFF ; BIPINCHANDRA N. DESAI ; LORI A. SCHRETZMAN ; NIZAL S. CHANDRAKUMAR ; SCOTT B. MOHLER ; YAPING WANG ; MIHIR D. PARIKH ; THOMAS D. PENNING ; BARBARA B. CHEN ; ISH K. KHANNA ; MARIA NGUYEN ; BALEKUDRU DEVADAS ; HWANG-FUN LU</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_BR0317600A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>por</language><creationdate>2005</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>HEATHER STENMARK</creatorcontrib><creatorcontrib>DALE P. SPANGLER</creatorcontrib><creatorcontrib>VICTORIA DOWNS</creatorcontrib><creatorcontrib>GLEN J. GESICKI</creatorcontrib><creatorcontrib>LISA WU</creatorcontrib><creatorcontrib>JOHN A. WENDT</creatorcontrib><creatorcontrib>MICHAEL B. TOLLEFSON</creatorcontrib><creatorcontrib>MARK RUSSELL</creatorcontrib><creatorcontrib>SRINIVASAN R. NAGARAJAN</creatorcontrib><creatorcontrib>ALBERT KHILEVICH</creatorcontrib><creatorcontrib>YI YU</creatorcontrib><creatorcontrib>MARK L. BOYS</creatorcontrib><creatorcontrib>RENEE M. HUFF</creatorcontrib><creatorcontrib>BIPINCHANDRA N. DESAI</creatorcontrib><creatorcontrib>LORI A. SCHRETZMAN</creatorcontrib><creatorcontrib>NIZAL S. CHANDRAKUMAR</creatorcontrib><creatorcontrib>SCOTT B. MOHLER</creatorcontrib><creatorcontrib>YAPING WANG</creatorcontrib><creatorcontrib>MIHIR D. PARIKH</creatorcontrib><creatorcontrib>THOMAS D. PENNING</creatorcontrib><creatorcontrib>BARBARA B. CHEN</creatorcontrib><creatorcontrib>ISH K. KHANNA</creatorcontrib><creatorcontrib>MARIA NGUYEN</creatorcontrib><creatorcontrib>BALEKUDRU DEVADAS</creatorcontrib><creatorcontrib>HWANG-FUN LU</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HEATHER STENMARK</au><au>DALE P. SPANGLER</au><au>VICTORIA DOWNS</au><au>GLEN J. GESICKI</au><au>LISA WU</au><au>JOHN A. WENDT</au><au>MICHAEL B. TOLLEFSON</au><au>MARK RUSSELL</au><au>SRINIVASAN R. NAGARAJAN</au><au>ALBERT KHILEVICH</au><au>YI YU</au><au>MARK L. BOYS</au><au>RENEE M. HUFF</au><au>BIPINCHANDRA N. DESAI</au><au>LORI A. SCHRETZMAN</au><au>NIZAL S. CHANDRAKUMAR</au><au>SCOTT B. MOHLER</au><au>YAPING WANG</au><au>MIHIR D. PARIKH</au><au>THOMAS D. PENNING</au><au>BARBARA B. CHEN</au><au>ISH K. KHANNA</au><au>MARIA NGUYEN</au><au>BALEKUDRU DEVADAS</au><au>HWANG-FUN LU</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina</title><date>2005-11-29</date><risdate>2005</risdate><abstract>"áCIDOS HETEROARILALCANóICOS COMO DERIVADOS DE ANTAGONISTAS DE RECEPTOR DE INTEGRINA". A presente invenção refere-se a composições farmacêuticas compreendendo compostos da Fórmula I, ou um seu sal farmaceuticamente aceitável, e métodos de inibição ou antagonização seletiva da ~ v~ ~ 6~ e/ou da ~ v~ ~ 5~ integrina sem significantemente inibir ~ v~ ~6~ integrina.
The present invention relates to pharmaceutical compositions comprising compounds of the Formula I, or a pharmaceutically acceptable salt thereof, and methods of selectively inhibiting or antagonizing the alphaVbeta3 and/or the alphaVbeta5 integrin without significantly inhibiting the alphaVbeta6 integrin.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | por |
| recordid | cdi_epo_espacenet_BR0317600A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T05%3A19%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HEATHER%20STENMARK&rft.date=2005-11-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EBR0317600A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |